Table 2.

Risk of death or hospitalization associated with randomization to digoxin stratified by improvement in renal function status.

	No IRF		Yes IRF
	HR (95% CI)	p	HR (95% CI)	p	p interaction
Death or Hospitalization
(n events = 418)
Unadjusted	0.99 (0.80–1.2)	0.910	0.60 (0.37–0.98)	0.042*	0.066*
Adjusted for baseline eGFR	0.99 (0.80–1.2)	0.909	0.56 (0.34–0.92)	0.023*	0.043*
Adjusted for 12 month eGFR	1.0 (0.80–1.2)	0.995	0.59 (0.33–0.92)	0.028*	0.029*
Adjusted for baseline characteristics	0.96 (0.77–1.2)	0.665	0.49 (0.29–0.81)	0.006*	0.026*
Death (n events = 269)
Unadjusted	1.0 (0.81–1.4)	0.742	0.59 (0.32–1.1)	0.100	0.095*
Adjusted for baseline eGFR	1.0 (0.81–1.4)	0.752	0.58 (0.31–1.1)	0.090	0.078*
Adjusted for 12 month eGFR	1.1 (0.82–1.4)	0.636	0.58 (0.31–1.1)	0.089	0.058*
Adjusted for baseline characteristics	1.0 (0.80–1.3)	0.793	0.60 (0.32–1.1)	0.120	0.064*
Hospitalization (n events = 277)
Unadjusted	0.96 (0.74–1.2)	0.725	0.58 (0.31–1.1)	0.082	0.149
Adjusted for baseline eGFR	0.96 (0.74–1.2)	0.721	0.51 (0.28–0.96)	0.035*	0.106
Adjusted for 12 month eGFR	0.97 (0.75–1.2)	0.802	0.50 (0.27–0.94)	0.030*	0.078*
Adjusted for baseline characteristics	0.92 (0.71–1.2)	0.523	0.44 (0.23–0.84)	0.013*	0.053*

Improvement in renal function (IRF) defined as a ≥20% increase in estimated globular filtration rate (eGFR) from randomization to one year. Baseline characteristics adjusted for: age, race, ejection fraction, heart rate, systolic blood pressure, NHYA class, diabetes mellitus, baseline use of digoxin, hydralazine, nitrates, diuretics, or angiotensin converting enzyme inhibitors, physical examination findings, cardio-thoracic ratio, and baseline eGFR.

^*Significant p value.